RxDoctor Payments Data

Shakoor Arain, MD

Cardiology · Okeechobee, FLNPI 1801874904

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $8,609 of the $12,978 with a category attached, or 66.3%. 18 manufacturers reported payments, led by Abbott at 44.1% of the total. Reporting peaked in 2024 at $5,256 and has fallen 64.0% since, to $1,894 in 2025. Among cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,978in general payments, 2019–2025

Across 182 payments — averaging $71.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Medtronic$6K
  • E.r. Squibb & Sons, L.L.C.$257
  • Astellas Pharma US Inc$227
  • Kestra Medical Technology Services, Inc.$205
  • Cvrx, Inc.$166
  • plus $773 from 12 others

What the payments were for

  • Travel & lodging$8,60966%
  • Food & beverage$4,18432%
  • Education$1851%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,978 in reported general payments places this provider in the 95th percentile of 45 cardiology providers in Florida.

See all cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$907,943
Medicare patients
787
Services billed
9,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$107,114
XareltoRivaroxaban29$35,867
EntrestoSacubitril/Valsartan13$23,197
Metoprolol Succinate217$2,753
Digoxin37$1,134
Losartan Potassium73$868
Potassium Chloride48$831
Atorvastatin Calcium91$681
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide37$611
ClopidogrelClopidogrel Bisulfate55$610
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$435
Furosemide74$426
Nifedipine ErNifedipine16$388
Nitroglycerin41$357
Diltiazem 24hr ErDiltiazem Hcl11$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$107,11494 claims
Johnson & JohnsonXarelto$65$35,86729 claims
NovartisEntresto$133$23,19713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 cardiology providers in Florida.

Other cardiology in Okeechobee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →